Biotechnology Companies in the News

Editor’s Note: The home page of the BioNJ Web site provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page (www.BioNJ.org) to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via e-mail at BioNJ@BioNJ.org.

February 25
**Aerie Pharmaceuticals Announces Study Results Supporting Additional Mechanism of Action for Lead Glaucoma Drug Candidate AR-13324**

February 24
**Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C**

**Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance**

February 21
**In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation**

February 20
**Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men**

**FDA Accepts for Review Merck’s Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine**
Zoetis Will Hold Its First Annual Meeting of Shareholders on May 13

Merck to Participate in the Citi 2014 Healthcare Conference

February 19
Antares Pharma to Participate in the 2014 RBC Capital Markets’ Global Healthcare Conference

Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat *Pseudomonas aeruginosa* in Cystic Fibrosis Patients
http://files.shareholder.com/downloads/INSMED/1395905095x0x726791/81813ac5-80c2-4be9-8b0b-fe41548b3a5b/INSM_News_2014_2_19_General.pdf

Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

Ezose Sciences Receives Grant from Michael J. Fox Foundation to Use GlycanMap® Technology in Parkinson’s Research
http://www.tmcnet.com/usubmit/2014/02/19/7684279.htm

Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutica

February 18
Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results

Update Pharma Receives Orphan Drug Approval

NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014
http://www.npssp.com/media?trxml_v=nrd&trxml_nr_id=1900956

Bard to Present at the Raymond James Institutional Investor Conference
http://investorrelations.crbard.com/phoenix.zhtml?c=91501&p=irol-newsArticle&ID=1900963&highlight=
February 17
MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner)

Samaritan Healthcare & Hospice Names James M. D'Onofrio Vice President of Strategic Business Initiatives

OncLive Announces 2014 Giants of Cancer Care Nominations Now Open

February 13
Billion-Dollar Biotech Valuations Fueling New IPO Surge

Alvogen launches Inflectra in Europe with Hospira

Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split

February 11
Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call

Celgene Corporation to Present at Investor Conferences in February and March

Dr. James Brown, COO, REGENX, Elected to SAFE-BioPharma Board of Directors

February 10
Protalex Announces Interim Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients

Bard to Present at Citi 2014 Global Healthcare Conference
February 6
ZRG Partners Life Sciences Hiring Index Shows Modest Gains in 4th Quarter

The Medicines Company to Announce Fourth Quarter and Full Year 2013 Financial Results on Wednesday, February 19, 2014

The Medicines Company to Host Acute Cardiovascular Care Investor and Analyst Meeting on March 7

February 5
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475

Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results

Protalex Announces Appointment of Marco M. Elser to Its Board of Directors

NPS Pharmaceuticals to Report 2013 Financial Results
http://www.npsp.com/media?trxml_v=nrd&trxml_nr_id=1897346

Elusys Completes Enrollment in Three Phase 3 Safety Studies of Its Anthrax Anti-Toxin, Eti-204, in Adult Volunteers
http://www.elusys.com/press_releases14/020514.html

Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference

BARDA Awards Contract Worth up to $90 Million to The Medicines Company/Rempex for Development of Gram-Negative Antibiotic

February 3
Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
ADMA Biologics Expands Plasma Collection Operations of ADMA BioCenters

Ablynx, Merck Launch Up to $2.3B Cancer Collaboration

Pfizer breast cancer drug succeeds in mid-stage trial
http://www.reuters.com/article/2014/02/03/us-pfizer-study-cancer-idUSBREA120OD20140203

Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca

January 30
Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results
http://ir.celgene.com/releasedetail.cfm?ReleaseID=822091

QPharma Announces Sales Effectiveness Workshop for Life Sciences

Bard Announces Fourth Quarter Results

Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium
http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=822234

Elusys Reports Its Anti-Toxin Achieved 100% Survival Rate Following Anthrax Challenge in Pre-Treatment Animal Study
http://www.elusys.com/press_releases14/013014.html

PTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership

January 28
VaxInnate Receives $2.1 million from New Jersey’s Technology Business Tax Certificate Transfer Program

Lingraphica Promotes Two and Adds Speech-Language Pathologists to Its Clinical Team
Merck Statement on FDA Advisory Committee Meeting for RAGWITEK™ (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet

Lexicon to Present at the BIO CEO & Investor Conference

January 24
Catalent Files Registration Statement for Initial Public Offering
http://www.reuters.com/article/2014/01/24/nj-catalent-pharma-idUSnBw245639a+100+BSW20140124

PTC Therapeutics Provides Update On CHMP Opinion For Conditional Approval Of Ataluren For Nonsense Mutation Duchenne Muscular Dystrophy

PTC Therapeutics Expands Management Team

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results

January 23
Protalex Announces Completion of $2.8 Million Private Placement

John Theurer Cancer Center Announces Positive Results with New Targeted Biological in Indolent Non-Hodgkin Lymphoma

Wipro Cited as a Leader in Worldwide Life Science Manufacturing and Supply Chain ITO by Independent Research Firm

STENTYS 2013 Annual Revenues Up 34% From 2012

Derma Sciences Announces Commencement of Public Offering of Common Stock
January 22
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014

Biocon Collaborates with Advaxis for ‘ADXS-HPV’ A Novel Cancer Immunotherapy

Giants of Cancer Care Awards Program Advisory Panel Grows by Leaps and Bounds

AZ diabetes combo Xigduo approved in Europe
http://www.pharmatimes.com/Article/14-01-22/AZ_diabetes_combo_Xigduo_approved_in_Europe.aspx

Joint Program In Spinal Muscular Atrophy Enters First Stage Of Clinical Development
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=820410

January 21
Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study
http://www.businesswire.com/news/home/20140121005860/en/Advaxis-Announces-Patient-Dosed-Phase-12-Head

IMS Health: Pharma Should Make Better Use of Social Media To Engage Patients and Improve the Use of Medicines
http://www.imshealth.com/portal/site/imshealth/menuitem.c76283e8bf81e98f53c753c71ad8c22a/?vgnextoid=ebc072cc270b3410VgnVCM1000076192ca2RCRD&vgnextchannel=ba11e590cb4dc310VgnVCM100000a48d2ca2RCRD&vgnextfmt=default

January 16
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative

January 15
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children

Advaxis Launches Online Communication Channels
Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine

Amgen, MGH, Broad Form IBD Therapeutics Initiative

January 14
Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products

January 13
U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes

Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference

Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma

Merck’s anti-blood clot drug should be approved: FDA review
http://www.reuters.com/article/2014/01/13/us-merck-vorapaxar-idUSBREA0C0SZ20140113

Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results

Sanofi to buy 12 pct of Alnylam, expands rare-disease drug deal
http://in.reuters.com/article/2014/01/13/sanofi-alnylam-idINL2N0KN0G120140113

Amicus Therapeutics Provides Full-Year 2014 Strategic Outlook and Financial Guidance
http://files.shareholder.com/downloads/AMTX/2893799923x0x717980/8dec73ba-00cd-44d7-9600-9eddcc4707a7d/FOLD_News_2014_1_13_General.pdf

Lexicon Announces Focus on Late-Stage Development Programs and Preparation for Commercialization
FDA Grants QIDP Designation to The Medicines Company’s Investigational Antibiotic CarbaVance

Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014

Regeneron, Bayer to co-develop Eylea combination treatment
http://uk.reuters.com/article/2014/01/13/regeneron-jointventure-idUKL3N0KN4CT20140113

New Laboratory Test Helps Hospitals Detect Newly Emerging Strains of Drug-Resistant Superbug

January 10
Celorje Corporation to Present 2013 Unaudited Financial Results and Updated Financial Outlook at the 32nd Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=818558

Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference

January 9
Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals

Senesco to Present at Biotech Showcase™ 2014

First Patient in Cohort 4 Receives Infusion of Senesco’s Therapeutic Candidate, SNS01-T, For the Treatment of Multiple Myeloma and Non-Hodgkins Lymphoma in Phase 1b/2a Clinical Trial

GSK gets accelerated FDA approval for melanoma drug combo

Soligenix to Present at the 2014 Biotech Showcase in San Francisco
January 8
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

Advaxis to Present at Biotech Showcase™ 2014 in San Francisco

Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and Announces Multiple, Diverse, Early-Stage Collaborations with Academia and Biotech

NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook

Merck Receives FDA Approval for ISENTRESS®(raltegravir) for Pediatric Oral Suspension

STENTYS Expands Marketing of its Stents in Asia

AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga™ (dapagliflozin)

Lexicon to Present at the JP Morgan Healthcare Conference

January 7
ABRXANE® Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer

The Medicines Company to Participate in Upcoming JP Morgan Healthcare Conference

Lexicon to Present at the JP Morgan Healthcare Conference

January 6
Antares Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24

Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference

PTC Therapeutics to Present at the J.P. Morgan Healthcare Conference

Janssen Inks Up to $337.5M Cell Therapy Collaboration with Capricor

Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference

Soligenix Appoints Richard Straube, MD, as Chief Medical Officer

January 3
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara® in Europe
http://npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1887693

26% of Drug Manufacturers have Chief Medical Officers in Place

Thermo Fisher sells cell culture, other businesses to GE

January 2
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference

NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome
http://npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1887434

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Third Quarter Earnings

December 30
Senesco Announces Letter of Intent to Merge with Fabrus
Sanofi MS drug suffers setback in key U.S. market
http://www.reuters.com/article/2013/12/30/sanofi-lemtrada-idUSL6N0K90UO20131230

Voluntary Field Corrective Action Initiated for Vital Signs Device’s CO2 Multi Absorber Due to a Health Risk

Amicus Therapeutics Completes Debt Financing of Up to $25 Million -- Follows $15 Million Equity Financing

December 27
Regulatory Update on Cevira
http://www.photocure.com/Pressmedia/News/Regulatory-Update-on-Cevira/

Lundbeck gets EU marketing approval for Brintellix
http://www.reuters.com/article/2013/12/27/us-lundbeck-depression-idUSBRE9BQ0EC20131227

ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada
http://thrombogenics.com/content/thrombogenics%E2%80%99-jetrea%C2%AE-receives-positive-common-drug-review-canada-0

December 26
TPG-Backed Drugmaker Aptalis Files for $500 Million U.S. IPO

December 23
PTC Therapeutics Added to NASDAQ Biotechnology Index

December 20
Antares Pharma® Announces Notice of Allowance for New Patent on Reconstitutable Lyophilized Injectables

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2013 Financial Results

Bayer raises offer for Xofigo partner Algeta
http://www.pharmatimes.com/Article/13-12-20/Bayer_raises_offer_for_Xofigo_partner_Algeta.aspx
December 19
FDA Accepts For Review ELIQUIS® (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE

December 18
Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma

Bristol close to selling diabetes stake to Astra for $3 billion: WSJ
http://www.reuters.com/article/2013/12/19/us-bristol-astrazeneca-idUSBRE9BI00O20131219

December 17
John Theurer Cancer Center Leadership in Blood Cancer Research Highlighted at the 55th Annual American Society of Hematology (ASH) Meeting in New Orleans

Nautilus Neurosciences, Inc. Announces the Sale of CAMBIA® (Diclofenac Potassium for Oral Solution) to Depomed, Inc. for Total Consideration of Up to $53.7 Million

MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO™ (fluralaner)

Bristol-Myers Squibb Foundation Awards $3.28 Million in Grants to Support Mental Health Needs of U.S. Military Service Members Returning from Afghanistan and Iraq

December 16
Endo Health to acquire Nupathe for $105 million
http://www.reuters.com/article/2013/12/16/us-nupathe-offer-idUSBRE9BF0LR20131216

Everett Laboratories acquires Quinnova Pharmaceuticals
http://www.njbiz.com/article/20131216/NJBIZ01/131219779/Everett-Laboratories-acquires-Quinnova-Pharmaceuticals

Click Here to return to the main page